About US
Contact us
-
Another 5 years of dominance: Oncology, immunology will extend their lead as pharma's top fields through 2025Cancer and autoimmune diseases aren’t going anywhere. And so the scramble to develop next-gen treatments rages on. As a result, global spending on oncology and immunology medicines will significantly2021/5/6
-
Fierce Pharma Asia—BeiGene touts Q1, PARP inhibitor nod; Astellas culls muscle disease pactBeiGene's first-quarter sales jumped 104% year over year to $106 million as it started to benefit from demand surgingon new national reimbursement coverage. The Chinese biotech also won a local go-ah2021/5/6
-
Gene therapy 'development engine' scores $120M to beef up contract manufacturingLess than a year after launch, gene therapy biotech-CDMO hybrid Forge Biologics has scored another round of investor cash to grow its viral vector ambitions. The self-styled gene therapy “development2021/4/30
-
Just how much COVID-19 vaccine money is on the table? A whopping $157B through 2025, report saysDrugmakers who seized the opportunity to develop vaccines against the coronavirus are on their way to reaping significant revenues. Exactly how much money is on the table? In its annual forecast for2021/4/30
-
Pfizer weighs sale of Philly-area campus—where 2,000 once worked—as company mulls when and how to bring employees backNot only do corporations have to determine when to bring employees back into the office after more than a year of at-home work, but how. It’s a decision even major COVID-19 drugmakers are evaluating2021/4/28
-
Johnson & Johnson scores in talc appeals as NJ court knocks down $117M verdictJohnson & Johnson has been hit with billions in talc verdicts, but it's had mixed successin appeals. With a new decision Wednesday, the company chalked up its latest appeals win. A court in J&2021/4/28
-
BeiGene's Brukinsa turns in 'near best case scenario' against Imbruvica in key CLL trial: analystBeiGene’s argument for its BTK inhibitor Brukinsa is that it’s a better drug than AbbVie and Johnson & Johnson’s first-to-market Imbruvica in terms of both efficacy and safety. Now, it appears to2021/4/26
-
Forget the competition. Sanofi still plans to usher its COVID-19 shot across the finish lineOneof the topvaccine playersopted to call it quits on its COVID-19 research after delays and setbacks. There are plenty of options already on the market or close to it. But not Sanofi. The French dru2021/4/26
-
Seagen, Astellas eye fast FDA review for Padcev's expanded bladder cancer use, with all-important Keytruda combo data to comeSeagen and Astellas have stepped in the FDA fast lane to move Padcev into earlier bladder cancer treatment—and one step closer to the antibody-drug conjugate’s blockbuster forecast. The FDAputtwo Pad2021/4/21
-
As variants take hold, FDA revokes authorization of Eli Lilly's solo COVID-19 antibodyEli Lilly’s COVID-19 neutralizing antibody drug was the first of its kind to score FDA authorization against the illness in early November. Emerging coronavirus variants later threatened to mute the2021/4/21